You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Diabetes Articles
Popular Diabetes Articles
Highly Recommended Diabetes Articles
Send a link to this page to your friends and colleagues.
Drug manufacturer Novo Nordisk has applied to the U.S. Federal Drug Administration and the European Medicines Agency for approval of liraglutide, a human GLP-1 analog* that is taken once daily for the treatment of type 2 diabetes.
The company’s applications are based on a study of 6,500 type 2s, 4,200 of whom received liraglutide as a diet and exercise adjunct. Some of the drug’s recipients used it in combination with other medications used to treat diabetes, while others received it as a monotherapy.
Study participants initially averaged A1c levels of just under 8.5% and body weights of 175 to 200 pounds. At the end of liraglutide’s Phase III trial, 40 percent of participants had reached the ADA goal A1c of 7%. They also enjoyed a weight loss of 4.5 to 9 pounds.
The reductions in A1c percentages and weight were not unexpected—liraglutide is analogous to exenatide, whose commercial version, Byetta, has been a spectacularly successful type 2 treatment extolled for its glucose control and weight loss properties. (The FDA is now considering whether Byetta can qualify as a monotherapy.)
By late September, 2008, Novo Nordisk plans to file for approval to market liraglutide in Japan.
*GLP-1 (“glucagon-like peptide”) is an incretin hormone that stimulates the release of insulin from pancreatic beta cells.
Jun 19, 2008